Charlie Mamrak

Charlie Mamrak has a diverse work experience spanning over several industries. Charlie is currently the CEO and Board Director at DCN Dx, a company that specializes in contract research and development, manufacturing services, and products for rapid clinical assays. Charlie joined the company in November 2020 and continues to hold these positions.

Prior to their current role, Charlie worked as an Operating Advisor at Martis Capital from August 2019 to November 2020.

From April 2012 to April 2019, Charlie served as the CEO and Board Director at SeraCare Life Sciences, a company that focuses on research tools, reference materials, and quality control controls for genomics and molecular diagnostics.

Before that, they worked as an Operating Partner at Linden Capital Partners from September 2009 to April 2012.

Charlie also has experience as a CEO at PML Microbiologicals from December 2005 to March 2009. The company specializes in cell culture media and products for bioprocess support and infectious disease detection.

Charlie also held the role of CEO at TestPak, Inc. from May 2004 to December 2005.

Charlie's earlier professional experiences include roles such as VP/General Manager at Thermo Fisher Scientific from January 2000 to May 2004, Commercial Director at Sigma-Aldrich from February 1997 to January 2000, VP of Analytical Laboratory Operations at CH2M from May 1990 to April 1996, and Technical Manager at Corning Laboratories from November 1988 to April 1990.

Charlie Mamrak attended Moravian University from 1981 to 1985, where they earned their Bachelor of Science (BS) degree in Biology/Chemistry. Additionally, they studied Biomedical Engineering at Penn State University. However, the timeframe and completion details for their studies at Penn State University are not specified.